102 episódios

A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from Oregon Health & Science University.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.

Plenary Session Vinay Prasad, MD MPH

    • Ciência

A podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from Oregon Health & Science University.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.

    2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch

    2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch

    This week we're treating you to a recording of the Grand Rounds lecture on overdiagnosis and cancer screening that Dr. H Gilbert Welch gave at Oregon Health & Science University on October 30, 2019. Before the lecture, we take a moment to reiterate with renewed vigor our distaste for the POLO trial (first discussed in episode 1.64).

    POLO: doi.org/10.1056/NEJMoa1903387

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 13 min
    2.32 BONUS! Clinical Trials Part 1: Thinking Better About Cancer Medicine

    2.32 BONUS! Clinical Trials Part 1: Thinking Better About Cancer Medicine

    This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part one of a three-part series on clinical trials, titled "Thinking Better About Cancer Medicine".

    Back us on Patreon! www.patreon.com/plenarysession

    • 53 min
    2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali

    2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali

    This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials".

    Durations of Response: doi.org/10.6004/jnccn.2019.7345

    Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

    Back us on Patreon! www.patreon.com/plenarysession

    • 40 min
    2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray

    2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray

    This week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions from a Medical Student with Audrey Tran. We end this week's episode with a far-reaching interview with Dr. Ellie Murray (most people know her as Epi Ellie on Twitter and as the co-host of the podcast Casual Inference) on all things epidemiology.

    Check out Dr. Murray's excellent podcast here: https://casualinfer.libsyn.com/

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 47 min
    2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall

    2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall

    This week we wonder incredulously how this abstract from ASH titled "Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia" was selected as one of the top abstracts from the conference. In the second half of the episode we interview Dr. Sherrie Aspinall of the Veterans Administration on how to use real-world data. Her new paper is titled "Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration".

    Time from diagnosis to treatment in AML: https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2019-123717
    Targeted therapies for advanced RCC: doi.org/10.1002/cam4.2531

    Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 9 min
    2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon

    2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon

    We're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon.

    Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635

    Back us on Patreon! www.patreon.com/plenarysession

    • 1h 3 min

Top de podcasts em Ciência

Outros ouvintes também assinaram